Journal
JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 324, Issue 1-2, Pages 190-194Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2012.11.004
Keywords
Mefloquine; JC virus; Progressive multifocal leukoencephalopathy; Human immunodeficiency virus; Blood-brain barrier; CD4
Categories
Funding
- Research Committee of Prion Disease and Slow Virus Infection [H20-Nanchi-Ippan-013]
- Ministry of Education, Science, Sports and Culture of Japan [19790349, 22790446]
- Ministry of Health, Labour and Welfare of Japan [H24-AIDS-Wakate-002]
- Grants-in-Aid for Scientific Research [22790446, 19790349] Funding Source: KAKEN
Ask authors/readers for more resources
Although progressive multifocal leukoencephalopathy (PML) cases showing responses to mefloquine therapy have been reported, the efficacy of mefloquine for PML remains unclear. We report on the failure of mefloquine therapy in two Japanese patients with PML unrelated to human immunodeficiency virus. One of the patients was a 47-year-old male who had been treated with chemotherapy for Waldenstrom macroglobulinemia, and the other was an 81-year-old male with idiopathic CD4(+) lymphocytopenia. Diagnosis of PML was established based on MRI findings and increased JC virus DNA in the cerebrospinal fluid in both patients. Mefloquine was initiated about 5 months and 2 months after the onset of PML, respectively. During mefloquine therapy, clinical and radiological progression was observed, and JC virus DNA in the cerebrospinal fluid was increased in both patients. Both patients died about 4 months and 2 months after initiation of mefloquine, respectively. Further studies are necessary to clarify the differences between mefloquine responders and non-responders in PML (C) 2012 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available